Skip to main content
. 2018 Jun 3;14(9):1054–1066. doi: 10.7150/ijbs.25349

Figure 6.

Figure 6

Clinical relevance of CCL2 in gastric cancer. (a) Overexpression of SQSTM1 mRNA predicted shorter overall survival of gastric cancer patients. (b) Overexpression of CCL2 mRNA predicted shorter overall survival of gastric cancer patients. (c) Overexpression of SQSTM1 mRNA predicted shorter relapse free survival of gastric cancer patients. (d) Overexpression of CCL2 mRNA predicted shorter relapse free survival of gastric cancer patients. (e) The levels of CCL2 in health people and gastric cancer patients' serums were detected by ELSIA(health n=31, patients n=18). (f) The viability of conditional medium cultured SGC7901 cells in the presence or absence of CCL2 neutralize antibody and cisplatin were determined by CCK-assay. (**P<0.01, ***P<0.001)